MarketBeat
21 Nov 2026, 18:13 UTC · 1h ago
Mesoblast Eyes Heart Failure Filing as Back Pain Trial and RYONCIL Expansion Advance
Impact · against what's priced in
Mesoblast gains material catalysts from a new regulatory pathway for heart failure (LVAD) and a substantial TAM expansion for RYONCIL into adults. The reported high gross margins and debt consolidation further improve the company's fundamental scalability and balance sheet.
- MESO+0.60
No priced-in read yet





